GDC-0199
Showing 1 - 25 of 259
Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia Trial in Columbus (drug, biological, other)
Active, not recruiting
- Chronic Lymphocytic Leukemia
- Refractory Chronic Lymphocytic Leukemia
- Bcl-2 Inhibitor GDC-0199
- +5 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Oct 29, 2021
T-Cell Lymphoma Relapsed, T-Cell Lymphoma Refractory Trial in Italy (Venetoclax)
Active, not recruiting
- T-Cell Lymphoma Relapsed
- T-Cell Lymphoma Refractory
-
Aviano, Italy
- +12 more
Dec 20, 2022
Chronic Lymphocytic Leucemia Trial in Cologne (Bendamustine, GA101, ABT-199)
Active, not recruiting
- Chronic Lymphocytic Leucemia
- Bendamustine
- +2 more
-
Cologne, GermanyGerman CLL Study Group
Sep 14, 2022
Chronic Lymphocytic Leukemia Trial in Houston (Ibrutinib, Venetoclax)
Recruiting
- Chronic Lymphocytic Leukemia
- Ibrutinib
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Sep 21, 2022
Chronic Myelomonocytic Leukemia Trial in Houston (Azacitidine, Tamibarotene, Venetoclax)
Not yet recruiting
- Chronic Myelomonocytic Leukemia
- Azacitidine
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Oct 10, 2023
Acute Myeloid Leukemia Trial in Houston (Azacitidine, Venetoclax, NK Cells)
Not yet recruiting
- Acute Myeloid Leukemia
- Azacitidine
- +2 more
-
Houston, TexasM.D. Anderson Cancer Center
Apr 17, 2023
Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia Trial in
Not yet recruiting
- Recurrent Chronic Lymphocytic Leukemia
- +3 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jan 10, 2023
B Acute Lymphoblastic Leukemia, Ph-Negative ALL, High Risk Acute Lymphoblastic Leukemia Trial (Azacitidine Injection,
Not yet recruiting
- B Acute Lymphoblastic Leukemia
- +2 more
- Azacitidine Injection
- +2 more
- (no location specified)
Oct 15, 2023
Secondary Myelodysplastic Syndrome, Therapy-Related Myelodysplastic Syndrome Trial in Columbus (Azacitidine, Quality-of-Life
Recruiting
- Secondary Myelodysplastic Syndrome
- Therapy-Related Myelodysplastic Syndrome
- Azacitidine
- +3 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Dec 1, 2022
Acute Myeloid Leukemia in Remission, FLT3 Gene Mutation, Hematologic and Lymphocytic Disorder Trial in Houston (Azacitidine,
Recruiting
- Acute Myeloid Leukemia in Remission
- +5 more
-
Houston, TexasM D Anderson Cancer Center
Dec 13, 2022
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Houston (Pirtobrutinib, Venetoclax)
Recruiting
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
-
Houston, TexasM D Anderson Cancer Center
Nov 17, 2022
Acute Myeloid Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia Trial in Houston (Decitabine, Quizartinib,
Recruiting
- Acute Myeloid Leukemia
- +4 more
- Decitabine
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Jan 27, 2023
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Atlanta (Tocilizumab, Venetoclax)
Recruiting
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Tocilizumab
- Venetoclax
-
Atlanta, GeorgiaEmory University Hospital/Winship Cancer Institute
Jan 24, 2023
Chronic Lymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma Trial in Houston
Active, not recruiting
- Chronic Lymphocytic Leukemia
- +5 more
- Ibrutinib
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Oct 12, 2022
Waldenstrom Macroglobulinemia, B-Cell Lymphoproliferative Disorder Trial in Boston (Pirtobrutinib, Venetoclax, Allopurinol)
Not yet recruiting
- Waldenstrom Macroglobulinemia
- B-Cell Lymphoproliferative Disorder
- Pirtobrutinib
- +2 more
-
Boston, Massachusetts
- +2 more
Feb 18, 2023
Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Duarte (8-Chloroadenosine,
Recruiting
- Acute Myeloid Leukemia
- +2 more
-
Duarte, CaliforniaCity of Hope Medical Center
Aug 15, 2022
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Columbus (Acalabrutinib, Obinutuzumab, Venetoclax)
Recruiting
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Acalabrutinib
- +2 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Nov 2, 2022
Blastoid Variant Mantle Cell Lymphoma, CCND1 Protein Overexpression, CD20 Positive Trial in Houston (Acalabrutinib, Venetoclax)
Recruiting
- Blastoid Variant Mantle Cell Lymphoma
- +8 more
-
Houston, TexasM D Anderson Cancer Center
Dec 5, 2022
Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Chronic Lymphocytic, Small-Cell Lymphoma Trial (Nemtabrutinib, Venetoclax,
Not yet recruiting
- Leukemia, Lymphocytic, Chronic, B-Cell
- +5 more
- Nemtabrutinib
- +2 more
- (no location specified)
Jul 21, 2023
Chronic Lymphocytic Leukemia, Richter Syndrome, Small Lymphocytic Lymphoma Trial in Rochester (Acalabrutinib, Durvalumab,
Recruiting
- Chronic Lymphocytic Leukemia
- +2 more
- Acalabrutinib
- +2 more
-
Rochester, MinnesotaMayo Clinic in Rochester
Jan 4, 2023
Acute Myeloid Leukemia Trial in Sacramento (Azacitidine, Uproleselan, Venetoclax)
Recruiting
- Acute Myeloid Leukemia
- Azacitidine
- +2 more
-
Sacramento, CaliforniaUniversity of California Davis Comprehensive Cancer Center
Aug 12, 2022
Hematopoietic and Lymphoid Cell Tumor, Recurrent Acute Biphenotypic Leukemia, Recurrent Acute Myeloid Leukemia Trial in Houston
Recruiting
- Hematopoietic and Lymphoid Cell Neoplasm
- +6 more
- Omacetaxine Mepesuccinate
- Venetoclax
-
Houston, TexasM D Anderson Cancer Center
Dec 31, 2022
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Duarte (Decitabine, Navitoclax, Venetoclax)
Recruiting
- Recurrent Acute Myeloid Leukemia
- Refractory Acute Myeloid Leukemia
- Decitabine
- +2 more
-
Duarte, CaliforniaCity of Hope Medical Center
Aug 15, 2022
Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma, Acute Myeloid Leukemia (AML) Trial (Venetoclax)
Available
- Chronic Lymphocytic Leukemia (CLL)
- +6 more
- (no location specified)
Mar 28, 2022